ARYL AND HETEROARYL COMPOUNDS, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF GALACTOCEREBROSIDASE
The application is directed to compounds of formulae (IA) and (IB): (IA) and (IB), and their salts and solvates, wherein R1a, R2a, A1, A2, A3, A4, R1b, R2b, B1, B2, B3, and G are as set forth in the specification, as well as to methods for their preparation, pharmaceutical compositions comprising th...
Saved in:
Main Authors | , , , |
---|---|
Format | Patent |
Language | English French |
Published |
03.06.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The application is directed to compounds of formulae (IA) and (IB): (IA) and (IB), and their salts and solvates, wherein R1a, R2a, A1, A2, A3, A4, R1b, R2b, B1, B2, B3, and G are as set forth in the specification, as well as to methods for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of, e.g., lysosomal storage diseases, such as Krabbe's disease, and α-synucleinopathies, such as Parkinson's disease.
La présente invention concerne des composés de formule (IA) et (IB), (IA) et (IB), et leurs sels et solvates, dans les formules, R1a, R2a, A1, A2, A3, A4, R1b, R2b, B1, B2, B3, et G sont tels que définis dans la spécification, ainsi que des procédés pour leur préparation, des compositions pharmaceutiques les comprenant, et leur utilisation pour le traitement et/ou la prévention, par exemple, de maladies de stockage lysosomal, telles que la maladie de Krabbe, et les α-synucléinopathies, telles que la maladie de Parkinson. |
---|---|
Bibliography: | Application Number: WO2020IB61156 |